Moderna releases positive R&D news ahead of earnings, shares surge 13% to hit new year-to-date high

BlockBeats news, November 5 — Moderna's stock closed up approximately 13.1%, about 5.11% higher than the 52-week high set on October 21, with market capitalization surpassing $100 billion. The company is set to release its third-quarter earnings report on November 6, with the market also watching its vaccine business and oncology therapy development progress.

On the news front, the Ebola candidate vaccine mRNA-1469 received a recommendation from the WHO Technical Advisory Group to advance to Phase II/III studies, and early clinical data for another multiple myeloma candidate therapy, mRNA-2808, was also selected for an oral presentation at the American Society of Hematology annual meeting.

According to TradingBeats monitoring, the MRNA contract on Hyperliquid touched $268.31 earlier this morning and was last reported at $257.05 at press time. Trading activity also rose in tandem.

Its 24-hour trading volume rose to $48.02 million from about $20.48 million at the same time yesterday, an increase of about 134.5%; notional open interest rose to $27.4 million from $21.29 million, an increase of about $6.11 million, or 28.7%.

The rally has put large short positions under pressure. The largest short holder still holds a MRNA short position of about $11.58 million at an average price of about $211, currently sitting on an unrealized loss of about $2.086 million.